Jojima, T., Wakamatsu, S., Kase, M., Iijima, T., Maejima, Y., Shimomura, K., . . . Aso, Y. (2019). The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int J Mol Sci.
Citação norma ChicagoJojima, Teruo, et al. "The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association With SGLT2 Expression in Hepatocellular Carcinoma." Int J Mol Sci 2019.
Citação norma MLAJojima, Teruo, et al. "The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association With SGLT2 Expression in Hepatocellular Carcinoma." Int J Mol Sci 2019.